Ultragenyx Pharmaceutical (RARE) reported a Q3 net loss late Tuesday of $1.40 per diluted share, narrowing from a loss of $2.23 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.48.
Revenue in the three months ended Sept. 30 rose to $139.5 million from $98.1 million a year earlier. Analysts surveyed by Capital IQ expected $135.3 million.
The company expects 2024 revenue of $530 million to $550 million. Analysts polled by Capital IQ expect $537 million.
Shares of the company fell 5.8% in recent after-hours activity.
Price: 49.17, Change: -3.01, Percent Change: -5.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。